Clinical Trials Browser

Phase EARLY_PHASE1 × Multiple Sclerosis × 1 year × Clear all

Multiple Sclerosis, Myasthenia Gravis, Recurrence, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Not yet recruiting

15 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica

NCT06939166 2025-12-15

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Recruiting

12 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trials

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases